Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results from a tocilizumab sJIA phase III clinical trial.

被引：0
|
作者：
Yokota, Shumpei
Imagawa, Tomoyuki
Mori, Masaaki
Takei, Syuji
Yoshifumi, I
Iwata, Naomi
Tomiita, Minako
Miyoshi, Mari
Aihara, Yuko
Murata, Takuji
Abukawa, Daiki
Nishimoto, Norihiro
Kishimoto, Tadamitsu
机构：
[1] Yokohama City Univ, Sch Med, Dept Pediat, Yokohama, Kanagawa 232, Japan
[2] Kagoshima Univ, Sch Med, Kagoshima 890, Japan
[3] Aichi Childrens Hlth & Med Ctr, Obu, Japan
[4] Chiba Univ, Chiba, Japan
[5] Kobe Childrens Hosp, Kobe, Hyogo, Japan
[6] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa 232, Japan
[7] Osaka Med Coll, Takatsuki, Osaka 569, Japan
[8] Miyagi Childrens Hosp, Sendai, Miyagi, Japan
[9] Osaka Univ, Osaka, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S327 / S327
页数：1
相关论文
共 31 条
  • [1] Proof of principle of the efficacy of IL-6 receptor blockade in severe systemic juvenile idiopathic arthritis (SJIA)
    Woo, P
    Wilkinson, N
    Prieur, A
    Southwood, T
    Leone, V
    Livermore, P
    Wythe, H
    Thomson, D
    Kishimoto, T
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 84 - 84
  • [2] Functional interleukin-6 (IL-6) polymorphisms in systemic juvenile idiopathic arthritis (sJIA): The G/C polymorphism at-174 has a dominant influence on transcription
    Jeffery, R. C.
    Luong, L.
    Fishman, D.
    Xia, C.
    Humphries, S.
    Woo, P.
    [J]. RHEUMATOLOGY, 2001, 40 : 47 - 48
  • [3] Efficacy and safety of tocilizumab in patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week data from the Phase 3 TENDER trial
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Calvo, I.
    Cutica, R.
    Malattia, C.
    Schneider, R.
    Woo, P.
    Wouters, C.
    Xavier, R.
    Zemel, L.
    Wright, S.
    Kenwright, A.
    Lovell, D.
    Martini, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 371 - 371
  • [4] EFFICACY AND SAFETY OF TOCILIZUMAB (TCZ) IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): 2-YEAR DATA FROM TENDER, A PHASE 3 CLINICAL TRIAL
    De Benedetti, F.
    Brunner, H.
    Ruperto, N.
    Kenwright, A.
    Devlin, C.
    Calvo, I.
    Cuttica, R.
    Ravelli, A.
    Schneider, R.
    Eleftheriou, D.
    Wouters, C.
    Xavier, R.
    Zemel, L.
    Baildam, E.
    Burgos-Vargas, R.
    Dolezalova, P.
    Garay, S. M.
    Joos, R.
    Grom, A.
    Wulffraat, N.
    Zuber, Z.
    Zulian, F.
    Lovell, D.
    Martini, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 425 - 425
  • [5] The correlations of serum interleukin-6 (il-6) levels and serum soluble il-6 receptor levels with disease activity in systemic juvenile idiopathic arthritis patients with and without tocilizumab treatment
    Butsabong Lerkvaleekul
    Sirisucha Soponkanaporn
    Soamarat Vilaiyuk
    [J]. Pediatric Rheumatology, 12 (Suppl 1)
  • [6] Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6
    Shimizu, Masaki
    Nakagishi, Yasuo
    Kasai, Kazuko
    Yamasaki, Yuichi
    Miyoshi, Mari
    Takei, Syuji
    Yachie, Akihiro
    [J]. CYTOKINE, 2012, 58 (02) : 287 - 294
  • [7] Long-term Efficacy and Safety of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results From a Phase III
    Brunner, Hermine
    Ruperto, Nicolino
    Quartier, Pierre
    Constantin, Tamas
    Alexeeva, Ekaterina
    Kone-Paut, Isabelle
    Marzan, Katherine
    Wulffraat, Nico
    Schneider, Rayfel
    Padeh, Shai
    Chasnyk, Vyacheslav
    Wouters, Carine
    Kuemmerle-Deschner, Jasmin B.
    Kallinich, Tilmann
    Lauwerys, Bernard
    Haddad, Elie
    Nasonov, Evgeny L.
    Trachana, Maria
    Vougiouka, Olga
    Leon, Karolynn
    Vritzali, Eleni
    Lheritier, Karine
    Martini, Alberto
    Lovell, Daniel
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69 : 64 - 66
  • [8] In-vitro Influence of TNF-α, IL-1 and IL-6 Antagonists (Biologicals) of the Cytokine Network in Patients with systemic juvenile idiopathic Arthritis (sJIA)
    Robinson, B.
    Kirchner, M.
    Sonnenschein, A.
    Mannhardt-Laakmann, W.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 95 - 95
  • [9] Tocilizumab in patients with Systemic Juvenile Idiopathic Arthritis (sJIA): 12-week Pharmacokinetic (PK) and Pharmacodynamic (PD) data from the Phase 3 TENDER Trial
    Ruperto, N.
    Zhang, A.
    Morcos, P. N.
    Huppertz, H.
    Minden, K.
    Myones, B.
    Onel, K.
    Siammopoulou, A.
    Silva, C.
    Kenwright, A.
    Roseti, S.
    De Benedetti, F.
    Lovell, D.
    Martini, A.
    Brunner, H.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (02) : 421 - 421
  • [10] Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study
    Brunner, Hermine I.
    Ruperto, Nicolino
    Quartier, Pierre
    Constantin', Tamas
    Alexeeva, Ekaterina
    Kone-Paut, Isabelle
    Marzan, Katherine
    Wulffraat, Nico
    Schneider, Rayfel
    Padeh, Shai
    Chasnyk, Vyacheslav
    Wouters, Carine
    Kuemmerle-Deschner, Jasmin B.
    Kallinich, Tilmann
    Lauwerys, Bernard
    Haddad, Elie
    Nasonov, Evgeny L.
    Trachana, Maria
    Vougiouka, Olga
    Leon, Karolynn
    Vritzali, Eleni
    Lheritier, Karine
    Martinis, Alberto
    Lovell, Daniel J.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
1234